Content area
Full text
3D models, P-08.07
Acute Myeloid Leukemia, P-03.04, P-03.05
Adapter CAR T cells, O-10.04, P-07.01
Adoptive T cell therapy, O-10.04, P-01.15, P-07.01
Affinity, P-02.04
allogeneic, O-13.03
AML, P-04.01, P-07.01
anti-ROR1 targeting, P-07.04
antisense, P-01.13
Artificial targets, P-02.03
Automation, P-08.03
B-cell lymphoma, P-07.05
Bispecific Antibody Therapy, P-04.01
Bladder cancer, O-10.01, P-08.01
BRD4, O-13.04
Cancer, O-10.03
cancer cell line, P-01.04
Cancer vaccine, O-09.03
CAR T cells, O-13.03, P-01.15, P-08.04, P-08.06, P-08.07
CAR T-cell therapy, P-07.05
CAR T-cells therapy, P-07.04
CAR-NK cell-based therapy, P-08.01
CAR-NK cells, O-10.01
CAR-T cell, O-10.02
CAR-T cell cytotoxicity, P-02.02
CAR-T cells, P-03.05
CAR-T...